TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?

Company Overview - TG Therapeutics (TGTX) shares increased by 7.5% to $29.74, following a significant trading volume, despite a prior 19.6% decline over the last four weeks [1] - The company reported preliminary sales of its drug Briumvi, generating $310 million in 2024, exceeding previous expectations of $300-$305 million [2] - For 2025, management anticipates total revenues of $540 million [2] Earnings Expectations - TGTX is projected to report quarterly earnings of $0.07 per share, reflecting a year-over-year increase of 177.8% [3] - Expected revenues for the upcoming quarter are $96.61 million, representing a 119.7% increase from the same quarter last year [3] - The consensus EPS estimate for TGTX has remained unchanged over the last 30 days, indicating a potential stability in earnings expectations [4] Industry Context - TG Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech (PBYI) also competes [4] - Puma Biotech's consensus EPS estimate has increased by 50% over the past month to $0.14, although this reflects a 54.8% decrease compared to the previous year [5]